Amanda B Peel1, Carolyn E Barlow2, David Leonard2, Laura F DeFina2, Lee W Jones3, Susan G Lakoski4. 1. University of Vermont College of Medicine, Burlington, VT, USA. 2. The Cooper Institute, Dallas, TX, USA. 3. Memorial Sloan Kettering Cancer Center, New York, NY, USA. 4. University of Vermont College of Medicine, Burlington, VT, USA; Department of Internal Medicine, Vermont Center on Behavior and Health, Vermont Cancer Center, University of Vermont, Burlington, VT, USA. Electronic address: susan.lakoski@uvm.edu.
Abstract
BACKGROUND: Cardiorespiratory fitness (CRF), a strong predictor of mortality, is impaired among cancer patients. There is limited data, however, regarding CRF levels in women diagnosed with gynecologic cancers. METHODS: We compared CRF among ovarian, endometrial, and cervical cancer cases (n=89) to age-matched controls (n=89) in the Cooper Center Longitudinal Study (CCLS). CRF was evaluated by a maximal treadmill exercise tolerance test using a modified-Balke protocol. Conditional logistic regression was used to test for case-control differences in cardiorespiratory fitness, after controlling for age and body mass index, and adhering to the matched pairs design. RESULTS: The mean ages of cancer cases and controls were 50.9 years and 51.1 years, respectively (p=0.81). Peak METs (1 MET=3.5 mL kg(-1)min(-1)) were 9.2 ± 2.0 in cancer cases compared to 10.0 ± 2.2 in controls (p=0.03). When stratifying by type of cancer, peak METs were 8.9 ± 2.2, 8.4 ± 1.9, 9.5 ± 2.0 for patients with ovarian, endometrial, and cervical cancer, respectively. A gynecological cancer diagnosis was associated with greater odds of having 1-MET lower CRF compared to controls (OR 1.31, 95% CI: 1.05-1.64, p=0.018), after controlling for age and BMI. CONCLUSION: Gynecologic cancer survivors were more likely to have a 1-MET lower CRF than controls. Given a 1-MET change in CRF is associated with a significant, we advocate for more robust research regarding CRF in gynecologic cancer patients.
BACKGROUND:Cardiorespiratory fitness (CRF), a strong predictor of mortality, is impaired among cancerpatients. There is limited data, however, regarding CRF levels in women diagnosed with gynecologic cancers. METHODS: We compared CRF among ovarian, endometrial, and cervical cancer cases (n=89) to age-matched controls (n=89) in the Cooper Center Longitudinal Study (CCLS). CRF was evaluated by a maximal treadmill exercise tolerance test using a modified-Balke protocol. Conditional logistic regression was used to test for case-control differences in cardiorespiratory fitness, after controlling for age and body mass index, and adhering to the matched pairs design. RESULTS: The mean ages of cancer cases and controls were 50.9 years and 51.1 years, respectively (p=0.81). Peak METs (1 MET=3.5 mL kg(-1)min(-1)) were 9.2 ± 2.0 in cancer cases compared to 10.0 ± 2.2 in controls (p=0.03). When stratifying by type of cancer, peak METs were 8.9 ± 2.2, 8.4 ± 1.9, 9.5 ± 2.0 for patients with ovarian, endometrial, and cervical cancer, respectively. A gynecological cancer diagnosis was associated with greater odds of having 1-MET lower CRF compared to controls (OR 1.31, 95% CI: 1.05-1.64, p=0.018), after controlling for age and BMI. CONCLUSION: Gynecologic cancer survivors were more likely to have a 1-MET lower CRF than controls. Given a 1-MET change in CRF is associated with a significant, we advocate for more robust research regarding CRF in gynecologic cancerpatients.
Authors: Susan K Lutgendorf; Eileen Shinn; Jeanne Carter; Susan Leighton; Keith Baggerly; Michele Guindani; Bryan Fellman; Marianne Matzo; George M Slavich; Marc T Goodman; William Tew; Jenny Lester; Kathleen M Moore; Beth Y Karlan; Douglas A Levine; Anil K Sood Journal: Gynecol Oncol Date: 2017-05-17 Impact factor: 5.482
Authors: Meghan Michalski; Kylie Rowed; Jessica A Lavery; Chaya S Moskowitz; Catherine Capaci; Guro Stene; Elisabeth Edvardsen; Neil D Eves; Lee W Jones; Jessica M Scott Journal: JACC CardioOncol Date: 2022-06-21
Authors: Jessica M Scott; Emily C Zabor; Emily Schwitzer; Graeme J Koelwyn; Scott C Adams; Tormod S Nilsen; Chaya S Moskowitz; Konstantina Matsoukas; Neil M Iyengar; Chau T Dang; Lee W Jones Journal: J Clin Oncol Date: 2018-06-12 Impact factor: 44.544
Authors: Tianyi Wang; Mary K Townsend; A Heather Eliassen; Kathryn L Terry; Mingyang Song; Melinda L Irwin; Shelley S Tworoger Journal: Int J Cancer Date: 2021-05-21 Impact factor: 7.316
Authors: Ladislav Batalik; Katerina Filakova; Ivana Radkovcova; Filip Dosbaba; Petr Winnige; Daniela Vlazna; Katerina Batalikova; Marian Felsoci; Marios Stefanakis; David Liska; Jannis Papathanasiou; Andrea Pokorna; Andrea Janikova; Sebastian Rutkowski; Garyfallia Pepera Journal: Front Cardiovasc Med Date: 2022-04-15
Authors: Christine M Friedenreich; Linda S Cook; Qinggang Wang; Renée L Kokts-Porietis; Jessica McNeil; Charlotte Ryder-Burbidge; Kerry S Courneya Journal: J Clin Oncol Date: 2020-10-07 Impact factor: 44.544